Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP72 monotherapy and in combination with Gemcitabine in pancreatic cancer
NCT04338763Phase 1Recruiting
- Sponsor
- Rise Biopharmaceuticals, Inc.
- Start
- Apr 2021
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of RP-72 in pancreatic cancer (PC) (2 arms), sponsored by Rise Biopharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase II Dose at 28 days. Started Apr 2021; status: recruiting.
02
Drugs
RP-72
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04338763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338763.